Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in blood and tumor tissue samples from patients with Wilms tumor.
|Kidney Cancer Renal Failure||Genetic: mutation analysis Genetic: polymerase chain reaction Other: laboratory biomarker analysis|
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Pilot Case-Control Study of WT1 Mutations in Wilms Tumor Patients Who Develop ESRD|
- Higher incidence of ESRD in non-syndromic WT patients with germline WT1 mutations than WT patients without WT1 mutations
Biospecimen Retention: Samples With DNA
|Study Start Date:||August 2011|
|Primary Completion Date:||May 2016 (Final data collection date for primary outcome measure)|
- To determine whether Wilms Tumor (WT) patients without WT1-associated congenital anomalies or syndromes, but with end-stage renal disease (ESRD) unrelated to progressive bilateral tumors, carry germline WT1 mutations.
- To determine whether non-syndromic WT1 germline mutation carriers have a substantially higher incidence of ESRD than do WT patients who do not harbor WT1 mutations.
OUTLINE: Archived blood and tumor tissue specimens (or DNA isolated from these samples) are analyzed for WT1 mutations by gene sequencing and PCR.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01314391
|Principal Investigator:||Vicki Huff, PhD||M.D. Anderson Cancer Center|